Stryker Corporation filings document the regulatory record of a New York Stock Exchange-listed medical technology issuer with operations in MedSurg, Neurotechnology and Orthopaedics. Its 8-K reports cover operating results, financial-condition updates, material events, Regulation FD disclosures and exhibits tied to company press releases.
The filing record also describes governance and capital-structure matters, including definitive proxy materials, annual-meeting votes, director elections, auditor ratification, executive-compensation votes, common stock and listed senior unsecured notes. Recent material-event filings include cybersecurity incident disclosures and amendments describing operational and reporting updates connected to Stryker's information technology environment.
Stryker Corp (SYK) Form 4: VP & Chief Communications Officer Kimberly Ann Montagnino had 155 common shares withheld on 01-Aug-2025 (transaction code “F”) at $392.73 to cover tax liabilities on vested equity. Post-withholding, the executive still owns 1,195 shares directly and 13 shares indirectly through a 401(k). No derivative positions or additional trades were reported, and the filing does not cite a Rule 10b5-1 trading plan. Given the small size and tax-related nature, this insider activity is considered routine and unlikely to influence SYK’s valuation.